Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 18.9%, EPS grew 81.3%, free cash flow grew 19.1% and total debt fell 25.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow AUPH
Aurinia Pharmaceuticals Inc (AUPH) Piotroski F-score
Aurinia Pharmaceuticals Inc's Piotroski F-score for fiscal 2025 is 8 out of 9: 8 of nine tests of profitability, leverage and efficiency passed, up from 7 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 8 | 1.00 |
| FY2024 | 7 | 4.00 |
| FY2023 | 3 | (1.00) |
| FY2022 | 4 | 2.00 |
| FY2021 | 2 | (1.00) |
| FY2020 | 3 | (1.00) |
| FY2019 | 4 | 1.00 |
| FY2018 | 3 | 0.00 |
| FY2017 | 3 | 0.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 44.11% | 1.05% | Pass | 1 |
| Positive operating cash flow | 135.66m | 44.39m | Pass | 1 |
| Rising return on assets | 44.11% | 1.05% | Pass | 1 |
| Cash flow above net income | (151.54m) | 38.64m | Fail | 0 |
| Falling long-term leverage | 0.08 | 0.11 | Pass | 1 |
| Rising current ratio | 5.25 | 4.57 | Pass | 1 |
| No new shares issued | 134,367,000 | 143,057,000 | Pass | 1 |
| Rising gross margin | 88.46% | 87.99% | Pass | 1 |
| Rising asset turnover | 0.43 | 0.43 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 8 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc | 8 |
| HRMY Harmony Biosciences Holdings, Inc. compare | 5 |
| NVAX Novavax, Inc. compare | 5 |
| RXRX Recursion Pharmaceuticals, Inc. compare | 3 |
| FTRE Fortrea Holdings Inc. compare | 3 |
| VRDN Viridian Therapeutics, Inc. compare | 3 |
| CLDX Celldex Therapeutics, Inc. compare | 2 |
| SLS SELLAS Life Sciences Group, Inc. compare | 2 |
| IRON Disc Medicine, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover